How many investments has Pfizer Venture Investments made?

Pfizer Venture Investments has 148 tracked investments, 18 of which have exited.

What stage does Pfizer Venture Investments invest at?

Pfizer Venture Investments invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Pfizer Venture Investments's typical check size?

Pfizer Venture Investments typically writes checks of $5M – $20M.

What sectors does Pfizer Venture Investments focus on?

Pfizer Venture Investments focuses on AI & Machine Learning, Biotech, Healthtech, Medical Devices.

Does Pfizer Venture Investments lead rounds?

Yes, Pfizer Venture Investments leads investment rounds.

Who does Pfizer Venture Investments co-invest with?

Pfizer Venture Investments most often shares deals with New Enterprise Associates (NEA), RA Capital, OUP (Osage University Partners), among 198 tracked co-investors.

Pfizer Venture Investments

Corporate VC

Seed–Late Stage · 16 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Pfizer Venture Investments

Paths you didn't know you had: your email and LinkedIn already hold routes to the Pfizer Venture Investments team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Strategic venture investor that preserves founder independence by not taking product rights, offers Pfizer collaboration potential, drug-discovery and business development expertise, active China strategy, and pharma exits.

Invests inAI & Machine Learning Biotech Healthtech Medical Devices

Source: firm website, verified Aug 7, 2026.

Leave your own feedback

Stage

Seed–Late Stage

Check

$5M – $20M

Leads rounds

Leads

Instruments

Equity

Founded

2004

Tracked investments

148

Unicorns

IPOs

Acquisitions

Team · 16 people

from the firm's website & curated & public directories

Michael C. Diem· Vice President, WWBD / Senior Managing Partner

Senior Managing Partner of Pfizer Ventures with two decades of experience as an executive and investor in pharmaceutical and biotech. Previously held senior business development roles at Century Therapeutics, Amicus Therapeutics, Aevi Genomic Medicine, and AstraZeneca, and was a partner at GSK's corporate venture firm SR One. Holds an MD and MBA.

Anthony Barry· Executive Director, WWBD / Partner

Irena Melnikova· Executive Director, WWBD / Partner

Marie-Claire Peakman· Executive Director, WWBD / Partner· Singaporein

Marie-Claire Peakman is a Partner at Pfizer Ventures, where she invests in early-stage private biotechnology companies, and an Executive Director in Pfizer's Worldwide Business Development and Research & Development. She holds a B.Pharm.Hons. in Pharmacy and a Ph.D. in Physiology and Pharmacology from the University of Nottingham, completed postdoctoral work at Yale University, and has spent 26 years at Pfizer, including founding the Primary Pharmacology Group in 2009 and leading it for 12 years, during which it identified compounds including nirmatrelvir (Paxlovid), abrocitinib (Cibinqo), and ritlecitinib (Litfulo). She serves as Immediate Past Chair of the Board of Directors for the United Way of Southeastern Connecticut and Vice Chair on the Boards of Trustees for Lawr

Artem Smirnov· Partner, Pfizer Ventures || Executive Director, Pfizer Research & Development· Orange County, California, United Statesin

Christopher O'Donnell· Vice President, WWBD / Partner· Connecticutin

Christopher O'Donnell is a Partner and Vice President at Pfizer Ventures and a Board Member at Cartography Biosciences. He holds a B.S. in Chemistry from the University of Illinois and a Ph.D. in Organic Chemistry from the University of Wisconsin, Madison, with postdoctoral experience in synthetic chemistry at UC Irvine. At Pfizer, where he joined in 1999, O'Donnell has held roles as medicinal chemist, project leader, and manager, contributing to the discovery of clinical candidates in neuroscience programs and building the Antibody Drug Conjugate chemistry group in 2010, which has nominated fourteen conjugates for clinical development with seven entering clinical trials; he subsequently established the Applied Synthesis Technologies group in 2017 and is an author on over 50 publications and inventor on more than 20 patents.

Michael Baran· Partner· New York Cityin

Rana Al-Hallaq· Vice President, WWBD / Partner· New York Cityin

Partner and Head of Operations at Pfizer Ventures responsible for identifying, evaluating, and managing equity investments aligned with Pfizer's strategic directions, including current oversight of eight portfolio companies and several fund investments. Brings expertise from clinical development and business development roles at Pfizer and Allergan, with a background in neuroscience research.

Ama Amoah· Finance Director, Business Development· New York, New York, United Statesin

Ama Amoah is Finance Director, Business Development at Pfizer, where she leads business finance on equity investment decisions alongside the Pfizer Ventures and Pfizer Breakthrough Growth Initiative teams and serves as the finance point of contact for business development deals. She rejoined Pfizer in 2019 after earlier roles supporting investor relations and product development, and previously worked at Royal Dutch Shell in Norway on asset valuation and gas contract negotiations. She holds a BSc in Chemistry from McMaster University and an MBA from Simmons Graduate School of Management.

Andrew J. Muratore· Vice President & Chief Counsel, M&A and Licensing· New London County, Connecticut, United Statesin

Andrew J. Muratore is Vice President and Chief Counsel, M&A and Licensing at Pfizer, where he has served as lead counsel to Pfizer Ventures since joining the company in 2008. He advises the Pfizer Ventures team on transactional matters, securities, compliance, and governance, and has led significant Pfizer M&A efforts including the acquisitions of Global Blood Therapeutics, Biohaven, Medivation and Hospira. He previously worked at Covington & Burling LLP and holds a J.D. from New York University and a B.A. from Colgate University.

Boyoon Choi· Senior Corporate Counsel· New York, New York, United Statesin

Boyoon Choi is Senior Corporate Counsel at Pfizer, where they joined in 2021 and serve as co-counsel to Pfizer Ventures, advising on transactional and general legal matters related to its equity investing and portfolio management. Their work includes equity and debt financings, strategic fund investments, and M&A transactions such as the Seagen acquisition. Before Pfizer, Choi was legal counsel for a global pharmaceutical company and its corporate venture arm, as well as an asset manager, and holds a J.D. from Columbia University and a B.A. from Barnard College.

Sophia Wood· Executive Assistant· Orange County, California, United Statesin

Sophia Wood is the Executive Assistant for the Pfizer Ventures team, which she joined in 2018, providing administrative support such as managing schedules and coordinating meetings. Before Pfizer, she held administrative roles at Mount Sinai School of Medicine, NYU Langone Medical Center, St. Vincent's Medical Center, and Memorial Sloan-Kettering Cancer Center.

Gillian Akai· Vice President and Chief Counsel, M&A and Licensing· Toronto, Ontario, Canadain

Gillian Akai serves as Senior Vice President, General Counsel, Communications and Corporate Secretary at Maple Leaf Foods Inc. Her experience spans the legal, risk, human resources, and communications functions, and she has advised the company's board, executive team, and employees. Her work has included managing business acquisitions and supporting growth in emerging areas of the business.

Joel Leong· Administrative Lead· Singaporein

Joel Leong is Director of Research & Analytics at Xora Innovation, where he conducts deep tech due diligence for early-stage investing and venture building. His background includes prior work in drug discovery and translational medicine.

Barbara Dalton· Vice President· New York, New Yorkin

Denis Patrick· New Yorkin

What they invest in

from 100 of 148 portfolio companies

Biotech ×91Healthtech ×56Medical Devices ×37AI & Machine Learning ×21Deep Tech ×20Digital Health ×14Longevity ×4Advanced Manufacturing ×3

HQs:United States×63United Kingdom×4Belgium×2Switzerland×2Germany×2Azerbaijan×1

Who they back

founder profiles across 46 portfolio companies

57%

solo founders

26 of 46 mapped founding teams

29%

repeat founders

of 34 founders with career history

~4 yrs

old at investment

median across 11 dated deals

Founding team size:solo founder×262 founders×113 founders×74+ founders×2

Where their founders studiedfrom 31 founders with education data

Massachusetts Institute of Technology ×6Stanford University ×3Stanford University Graduate School of Business ×3The University of North Carolina at Chapel Hill ×3Harvard University ×2Stanford University School of Medicine ×2University of California, Berkeley ×2University of California, San Francisco ×2

What their founders studiedfrom 32 founders with field-of-study data

Life Sciences ×9Medicine ×8Engineering ×7Chemistry ×6Business & Management ×2Computer Science ×2Social Sciences ×2

Where their founders worked beforefrom 34 founders with career history

Atlas Venture ×2Avalon BioVentures ×2Fred Hutch ×2HotSpot Therapeutics ×2Linköping University ×2Massachusetts Institute of Technology ×2Stanford University ×2The Scripps Research Institute ×2

20 founders hold a PhD · 3 hold an MBA (of 32 with degree data)

Investments · 148 tracked

founders shown can be your intro path

By year:2024 · 1 2023 · 1 2022 · 1 2021 · 1 2020 · 2 2019 · 2 2018 · 1 2017 · 3 2016 · 1 2015 · 215 dated

4D Molecular Therapeutics4dmoleculartherapeutics.com inNASDAQ: FDMT

4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.

BiotechHealthtechEmeryville, US

David Kirn(Executive Officer, Director)in David Schaffer(Director)inTheresa Janke(Executive Officer)in

BoardSharon Tetlow(Director)Margi McLoughlin(Director)

Co-investorsAmzak Health Berkeley Catalyst BOLD Longevity Chiesi Ventures Pappas Capital Ridgeback Capital +7 more

Bolt Biotherapeuticsboltbio.com in 𝕏NASDAQ: BOLT

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

Dr. Edgar G. Engleman(Founder)

Co-investorsPivotal Life Sciences RA Capital Samsara BioCapital Sofinnova Ventures Vivo Capital Nan Fung Life Sciences +3 more

CytomX Therapeuticscytomx.com in 𝕏NASDAQ: CTMX

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.

BiotechHealthtechSouth San Francisco, US

Sean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)in Chris Ogden(Chief Financial Officer)in

Co-investorsATEL Ventures Canaan Partners Longitude Capital Wellington Management OrbiMed Third Rock Ventures

Enliven Therapeuticsenliventherapeutics.com inNASDAQ: ELVN

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)in Ben Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5AM Ventures OrbiMed Roche Venture Fund ARCH Venture Partners Bay City Capital Janus Henderson Investors +2 more

Ginkgo Bioworksginkgo.bio in 𝕏NYSE: DNA

Ginkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology.

AgTechAI & Machine LearningBiotechDeep TechHealthtechRoboticsBoston, US

Jason Kelly(Founder)in Reshma Shetty(Founder)in Barry Canton(Founder)in Austin Che(Founder)inTom Knight(Founder)inBartholomew Canton(Executive Officer)

Co-investors11.2 Capital Allen Institute for AI (AI2) Incubator Azure Capital Partners B3 Holding Blue Owl Capital Cannage Capital +62 more

ImaraNASDAQ: ELVNMar 2019 · $63Macquired by Enliven Therapeutics · Feb 2023

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Co-investorsBay City Capital New Enterprise Associates (NEA)RA Capital Alexandria Arix Bioscience JMI Equity +3 more

Kymera Therapeuticskymeratx.com in 𝕏NASDAQ: KYMR

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in Bruce Booth(Chair)in

Co-investorsAtlas Venture Avoro Capital Advisors Bain Capital Life Sciences Bessemer Venture Partners Hatteras Venture Partners MRL Ventures Fund +7 more

Mirna Therapeuticsblogmedicina.com 𝕏OTC: SYBX

A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.

BiotechMedia & EntertainmentAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)in Paul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Co-investorsNew Enterprise Associates (NEA)Correlation Ventures OrbiMed OUP (Osage University Partners)Pfizer Ventures Sofinnova Ventures

NextCurenextcure.comNASDAQ: NXTC

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)in Udayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)in Sourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in

Co-investorsBay City Capital Canaan Partners LAV Lilly Asia Ventures Quan Capital Sofinnova Ventures +4 more

NovoCurenovocure.com in 𝕏NASDAQ: NVCR

Novocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer.

BiotechHealthtechMedical Devices

Yoram PaltiinWilliam F. Doyle(Executive Chairman)Frank Leonard(Chief Executive Officer)in

Co-investorsWindham Capital Partners

Pyxis Oncologypyxisoncology.com in 𝕏NASDAQ: PYXS

Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Thomas Civik(Interim Chief Executive Officer, Director)

Board David Steinberg(Executive Officer, Director)in Christoph Westphal(Director)Geeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)

Co-investorsAgent Capital LifeSci Venture Partners Longwood Fund RA Capital Trans-Pacific Technology Fund RTW Investments L.P.

Synlogicsynlogictx.com in 𝕏OTC: SYBX

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)inMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)in Paul Miller(Executive Officer)inAoife Brennan(Executive Officer)inTodd Shegog(Executive Officer)in

Co-investorsAtlas Venture CLI Ventures New Enterprise Associates (NEA)NSG Ventures Sofinnova Ventures Solasta Ventures +1 more

Reflexionmedicalreflexion.com in 𝕏Mar 2022

RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.

BiotechHealthtechMedical DevicesHayward, US

Samuel Mazin(Executive Officer, Director)inAkshay Nanduri(Executive Officer, Director)in

Board Jay Watkins(Director)in

Board seat Rana Al-Hallaq· per SEC Form D

Co-investorsAscension Ventures Catalio Capital Management, LP Sofinnova Partners Sonder Capital Venrock

Ablexisablexis.com

Ablexis develops the AlivaMab Mouse, a transgenic mouse platform for antibody drug discovery used by major pharmaceutical companies.

BiotechDeep Tech

Larry(CEO and Founder)

Co-investorsCalifornia Technology Ventures Third Rock Ventures

Adapsyn Bioscienceadapsyn.com in

Adapsyn Bioscience is a biotech company focused on discovering and developing microbial natural product small molecules for therapeutic applications by leveraging genomic and chemical biology approaches.

AI & Machine LearningBiotechDeep TechHamilton, CA

Nathan Magarvey(Founder)

Co-investorsGenesys Capital

AMRA Medical ABamramedical.com in 𝕏

AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLinköping, SE

Magnus Borga(Co-Founder)inOlof Dahlqvist Leinhard(Chief Executive Officer, Co-Founder)in

Co-investorsHealthCap Industrifonden

Anaveonanaveon.com in

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsNovartis Venture Fund Pontifax Venture Capital Forbion

Aquinnah Pharmaceuticalsaquinnahpharma.com

Aquinnah Pharmaceuticals develops oral small-molecule therapeutics targeting pathologic biomolecular condensates, such as stress granules formed by RNA-binding proteins, to slow neurodegenerative diseases including ALS and Alzheimer's disease.

BiotechHealthtechLongevityCambridge, US

Benjamin Wolozin(CSO & Co-founder)inDr. Glenn Larsen(Co-founder, President and CEO)Dr. Ben Wolozin(Co-Founder and Chief Scientific Officer)

Co-investorsAbbVie

Arkuda Therapeuticsarkudatx.com in

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsAtlas Venture Mission Biocapital Pfizer Ventures Pivotal Life Sciences

Arrakis Therapeuticsarrakistx.com in 𝕏

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)in David Neafus(Executive Officer)inRussell C. Petter(Executive Officer)

Board Colleen Cuffaro(Director)in Alan E. Walts(Director)in

Co-investorsCanaan Partners Pfizer Ventures Advent Life Sciences HBM Healthcare Investments HBM Partners Nextech Invest +2 more

Artios Pharmaartios.com in 𝕏

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsAndera Partners Dementia Discovery Fund M Ventures Novartis Venture Fund RA Capital Sofinnova Partners +6 more

Autifony Therapeuticsautifony.com in

Autifony Therapeutics is a privately funded biopharmaceutical company developing treatments for neurological conditions including Fragile X Syndrome and orphan epilepsy syndromes.

BiotechHealthtechMedical DevicesStevenage, GB

Charles H. Large(Founder and Chief Executive Officer)inGiuseppe Alvaro(Director)Daniel UmbrichtBarbara Domayne-HaymanMartin GunthorpeHannah Selin

Co-investorsSV Health Investors Dementia Discovery Fund Innovate UK

Autobahn Therapeutics, Inc.autobahntx.com inJun 2024

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.

BiotechDeep TechMedical DevicesSan Diego, US

Kevin Finney(Chairman, President and CEO)in John Borkholder(Executive Officer)in

Board Kristina Burow(Director)in Thomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

Co-investorsARCH Venture Partners Canaan Partners Monograph Capital Partners Samsara BioCapital Insight Partners Newpath Partners

BDbd.com in 𝕏

BD is a global medical technology company developing devices, systems, and solutions for medication administration, diagnostics, connected care, biopharmaceutical manufacturing, and interventional procedures.

Digital HealthHealthtechMedical DevicesFranklin Lakes, US

BioAtlabioatla.com inMar 2015

BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).

BiotechHealthtechMedical DevicesSan Diego, US

Jay M. Short(Executive Officer, Director)Richard A. Waldron(Executive Officer)inCarolyn Short(Director)

Co-investorsKeshif Ventures Pappas Capital HBM Healthcare Investments Pappas Capital Pfizer Ventures Soleus Capital

BioNTechbiontech.de in 𝕏

BioNTech develops immunotherapies that use the body's immune system to treat cancer, infectious diseases, and other serious illnesses.

BiotechHealthtech

Christoph Huber(Founder)Uğur Şahin(Founder)inÖzlem Türeci(Founder)

Co-investorsHM Venture Partners Salvia Andreessen Horowitz MIG Capital AG

BioNTechbiontech.com in 𝕏

BioNTech is a biotechnology company developing immunotherapies that use the body's immune system, combining multiple therapeutic modalities and biological targets to treat cancer, infectious diseases, and other serious conditions.

BiotechHealthtechMainz

Ozlem Tureci(Executive Officer)Ugur Sahin(Executive Officer)inSierk Poetting(Executive Officer)inSean Marett(Executive Officer)in Ryan Richardson(Executive Officer)in

Board Christoph Huber(Director)in

Co-investorsManta Ray Ventures MIG Capital AG Onsight Ventures Salvia

BlueLight Therapeuticsbluelighttx.com

BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Ariel G. Notcovich(Founder & CEO)Mark Gallop(CSO)Mira Chaurushiya(CBO)Anjanabha Saha(VP, Discovery)

Co-investors5AM Ventures Pfizer Ventures

Capstan Therapeuticscapstantx.com 𝕏

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)in Ramin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsFinchley Healthcare Ventures RA Capital Sofinnova Ventures Vida Ventures Alexandria Forbion

Cartography Biosciencescartography.bio in 𝕏

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.

AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US

Max Mumbach(Founding Scientist, Target Discovery)inJeffrey Verboon(Founding Scientist, Computational Biology)inAnsu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Founder)in

Co-investors8VC Andreessen Horowitz Artis Ventures Catalio Capital Management, LP Finchley Healthcare Ventures Global BioAccess Fund +9 more

Clovis Oncologyclovisoncology.com

Developed targeted cancer therapies with companion diagnostics (Rubraca); IPO'd in 2011 (NASDAQ: CLVS).

Patrick Mahaffy(Founder)in

Co-investorsAisling Capital Frazier Life Sciences New Enterprise Associates (NEA)Ridgeback Capital

Cortexymecortexyme.com

Casey Lynch(Founder)Kristen Gafric(Founder)Stephen Dominy(Founder)

Co-investorsDolby Family Ventures Sofinnova Partners

Crossbow Therapeuticscrossbowtx.com in

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)in Dmitri Wiederschain(Executive Officer)in

Board Alexandra Cantley(Director)inSakae Asanuma(Director)in Briggs Morrison(Executive Officer, Director, Promoter)in Irena Melnikova(Director)in

Co-investorsLifelink MPM BioImpact Biotechnology Value Fund Mirae Asset Venture Investment Pfizer Ventures Polaris Partners +1 more

Curve Therapeuticscurvetx.com in

Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets.

AI & Machine LearningBiotech

Co-investorsEpidarex Capital Columbus Venture Partners

DEM BioPharmadembiopharma.com

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

Nenad Grmusa(Chief Executive Officer)in John McCabe(Chief Financial and Operating Officer)in

Co-investorsAlta Partners Astellas Venture Management LLC DC Investment Partners Longwood Fund UTokyo Innovation Platform Co. Ltd.Insight Partners +1 more

Effector Therapeuticseffector.com

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in

BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Co-investorsAstellas Venture Management LLC Mission Bay Capital Mission Biocapital OUP (Osage University Partners)US Venture Partners Sofinnova Ventures

Eiger BioPharmaceuticalseigerbio.comNov 2015

BiotechSanta Clara, US

Jeffrey Glenn(Director)David Cory(Executive Officer, Director)

BoardNina Kjellson(Director)inEd Engleman(Director)

Co-investorsCanaan Partners Vivo Capital Vivo Ventures

Enara Bioenarabio.com in 𝕏

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.

BiotechDeep TechMedical Devices

George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in

Co-investorsRA Capital Samsara BioCapital SV Health Investors Pfizer Ventures Dementia Discovery Fund M Ventures

Enlaza Therapeuticsenlazatx.com in

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.

BiotechDeep TechSan Diego, US

Sergio Duron(Co-Founder & Chief Executive Officer)in Sanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in

Board Marcos Milla(Director)in Jay Lichter(Director)in Tighe Reardon(Executive Officer)

Co-investorsFrazier Life Sciences Lightspeed Venture Partners Samsara BioCapital Avalon BioVentures Pappas Capital J.P. Morgan Asset Management +1 more

Enodia Therapeuticsenodiatx.com in

Enodia Therapeutics develops small-molecule therapies that target protein degradation at the point of synthesis using a machine learning-enabled platform.

AI & Machine LearningBiotechDeep Tech

Yves Ribeill(CEO)

Co-investorsBpifrance Elaia Pfizer Ventures

Entelosentelos.com

Sam Holtzman(Founder)in

Co-investorsSofinnova Ventures Boulder Ventures

Epix Therapeuticsinacquired by Medtronic · Jan 2019 · $316M

Medtronic designs and develops medical technology for treating complex diseases.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investors8VC CWRU Technology Ventures Elevate Ventures Menlo Ventures Oak Investment Partners Questa Capital+5 more

EvolveImmune Therapeuticsevolveimmune.com inDec 2023

EvolveImmune develops immunotherapy treatments for cancer patients.

BiotechHealthtechMedical DevicesBranford, US

Stephen Bloch(Co-founder and Chief Executive Officer)inDonmienne Leung(Manager)Ian Taylor(Manager)Jay Fine(President, Research and Development)

Board Derek Yoon(Manager)inJasmina Marjanovic(Manager)in

Co-investorsSolasta Ventures Pfizer Ventures Elm Street Ventures Takeda Ventures

Flare Therapeuticsflaretx.com in

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.

AI & Machine LearningBiotechDeep TechHealthtech

Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in

Co-investorsNexTech Ventures Pfizer Ventures Third Rock Ventures Nextech Invest ShangBay Capital LLC Agent Capital

FoRx Therapeuticsforxtherapeutics.com in

FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors.

BiotechDeep TechHealthtechBasel, CH

Tarig Bashir(Chief Executive Officer (CEO))inJens Würthner(Chief Medical Officer (CMO))Frank Zenke(Chief Scientific Officer (CSO))in

Co-investorsM Ventures Novartis Venture Fund Omega Funds

G-CON Manufacturinggconbio.com in 𝕏

G-CON designs, manufactures, and installs prefabricated cleanroom systems for the biopharmaceutical, cell and gene therapy, and advanced therapy industries.

Advanced ManufacturingBiotechCleantechConstruction TechHardware

Robert Pedersen(Chief Executive Officer)

Co-investorsWP Global Partners

Genomic Healthgenomichealth.com in 𝕏

Genomic Health develops diagnostic tests and related services and runs health-equity initiatives aimed at improving access, awareness, and outcomes for patients and communities, including uninsured and underinsured populations.

BiotechDigital HealthHealthtechMedical Devices

Steve Shak(Founder)in Kevin Conroy(CEO)inRandy Scott(Founder)

Co-investorsKleiner Perkins Vedanta Capital

Grey Wolf Therapeuticsgreywolftherapeutics.com in

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

BiotechDigital HealthHealthtechMedical DevicesOxford, GB

Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in

Co-investorsAndera Partners Canaan Partners Oxford Science Enterprises British Patient Capital Earlybird Venture Capital Pfizer Ventures

Imcheckimchecktherapeutics.com inacquired by Clementia

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.

BiotechHealthtech

Daniel Olive(Founder)

Co-investorsAgent Capital Andera Partners Kurma Partners Pureos Bioventures Alexandria Bpifrance +4 more

Immunocodeximmunocodex.com

Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesBoston, US

Mark Carthy(Founder and CEO)Francisco J. Quintana(Scientific Founder)

ImmunOsimmunostherapeutics.com

Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.

BiotechHealthtechMedical Devices

Co-investorsBackbone Ventures BioMedPartners Gimv Lightspeed Venture Partners Mission Biocapital Pfizer Ventures +1 more

Interius BioTherapeuticsinteriusbio.com

BiotechPhiladelphia, US

Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in

BoardTomas Kiselak(Director)

Co-investorsAgent Capital DC Investment Partners Longwood Fund OUP (Osage University Partners)Quan Capital Bain Capital Life Sciences +3 more

Jnana Therapeuticsjnanatx.com in 𝕏Aug 2021acquired by Otsuka

Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.

AI & Machine LearningBiotechDeep TechAustin, US

Joel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)Annie C. Chen(Director)

Co-investorsAvalon BioVentures Bain Capital Life Sciences RA Capital Pfizer Ventures Polaris Partners Versant Ventures

Kestrel Therapeuticskestreltherapeutics.com in

Kestrel Therapeutics develops targeted cancer therapies focused on inhibiting KRAS mutations across all tumor types using structure-based drug design.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Frank G. Haluska(Executive Officer, Director)in

BoardOmar Khalil(Director)Nicholas Saccomano(Director)Barbara Sosnowski(Director)Andrew Phillips(Director)Denis Patrick(Director)

Co-investorsSection 32

Kinetakinetabio.com

BiotechSeattle, US

Shawn Iadonato(Executive Officer, Director)inRobert Hedequist(Executive Officer)Pauline Kenny(Executive Officer)inCharles Magness(Director)

Co-investorsKeiretsu Forum TSVC Wellcome Trust

Leviceptlevicept.com

Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.

BiotechHealthtechMedical Devices

Simon Westbrook(Founder and CSO)in

Co-investorsAdvent Life Sciences Gilde Healthcare Index Ventures Medicxi Pfizer Ventures Redwood Ventures

Mallinckrodtmallinckrodt.comAcquired

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.

Advanced ManufacturingBiotechHealthtechMedical Devices

Co-investorsARCH Venture Partners Cross Creek Advisors Signet Healthcare Partners Sofinnova Ventures

Mediar Therapeuticsmediartx.com in

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)in Rahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Co-investorsAgent Capital Gimv Longwood Fund Mission Biocapital Novartis Venture Fund Ono Venture Investment, Inc.+5 more

Mersana Therapeuticsmersana.com 𝕏Jun 2016Acquired

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).

BiotechHealthtechCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)

Co-investorsBain Capital Life Sciences F-Prime Capital Lightstone Ventures New Enterprise Associates (NEA)Nextech Invest Rho Ventures +3 more

Merusmerus.nl in

Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.

BiotechMedical DevicesUtrecht, NL

Ton Logtenberg(Executive Officer, Director)inMark Throsby(Executive Officer)in Hui Liu(Executive Officer)in John Crowley(Executive Officer)in L. Andres Sirulnik(Executive Officer)inLex Bakker(Executive Officer)in

Co-investorsAvoro Capital Advisors RA Capital Sofinnova Ventures

MindImmune Therapeuticsmindimmune.com

MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.

BiotechHealthtechKingston, US

Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)inStevin Zorn(Executive Officer, Director)in Isaac Stoner(CEO)in

BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)in

Co-investorsDolby Family Ventures Slater Technology Fund ARCH Venture Partners Pfizer Ventures

Mission Therapeuticsmissiontherapeutics.com in 𝕏

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

Co-investorsRoche Venture Fund Rosetta Capital Ltd.Sofinnova Partners SR One Capital Management IP Group

Mitokininmitokinin.com

Targeting mitochondria for neurodegenerative disease therapies.

BiotechNew York, US

Nicholas Hertz(Director)Doug Crawford(Director)Daniel de Roulet, Jr.(Executive Officer, Director)

BoardJohannes Fruehauf(Director)

Co-investorsMission Bay Capital Mission Biocapital

Montis Biosciencesmontisbio.com in

Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDroia Ventures Pfizer Ventures VIB Polaris Partners

Montis Biosciencesmontisbiosciences.com in

Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDroia Ventures Pfizer Ventures VIB

Mozart Therapeuticsmozart-tx.com

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in

Co-investorsARCH Venture Partners JDRF T1D Fund MRL Ventures Fund Ono Venture Investment, Inc.Sofinnova Partners AbbVie +6 more

NexImmuneneximmune.com in 𝕏

NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses.

BiotechMedical DevicesGaithersburg, US

Jonathan Schneck(Director)Alain Cappeluti(Executive Officer, Director)Kenneth Carter(Executive Officer, Director)

BoardJanis Naeve(Director)James Barrett(Director)

Co-investorsRapha Capital Management, LLC New Enterprise Associates (NEA)

Nimbus Therapeuticsnimbustx.com in

Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.

AI & Machine LearningBiotechDeep TechHealthtech

Co-investorsAccess Biotechnology Atlas Venture Bain Capital Life Sciences Dementia Discovery Fund GV (Google Ventures)Lightstone Ventures+4 more

Normunitynormunity.com in 𝕏

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)in William LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)

Co-investorsSanofi Ventures Taiho Ventures, LLC Pfizer Ventures Samsara BioCapital Canaan Partners Connecticut Innovations +6 more

Novosteoquincetx.com in 𝕏

Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T).

BiotechHealthtechWest Lafayette, US

Philip S. Low, Ph.D.(Executive Officer, Director)David Lamond(Director)Daniel Hasler(Director)Dirk Thye, M.D.(Executive Officer, Director)William J. Rutter(Director)Alex Andrianopoulos(Director)

Co-investorsBreakout Ventures Elevate Ventures

Nucleomenucleome.com

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM Ventures Oxford Science Enterprises British Patient Capital JJDC Pfizer Ventures

Palleon Pharmaceuticalspalleonpharma.com in 𝕏Sep 2020

Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.

BiotechDigital HealthMedical DevicesWaltham, US

Jim Broderick(Co-Founder)inJohn Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)Li Peng(Chief Scientific Officer)

Co-investorsMatrix Capital Management Pfizer Ventures SR One Capital Management BioHealth Innovation, Inc.Takeda Ventures Vertex Ventures HC

PrescriberPointprescriberpoint.com in

PrescriberPoint operates an AI-enabled medication access platform that helps clinicians get patients onto prescribed therapies by providing prescribing support, coverage and cost-savings lookups in one place.

AI & Machine LearningDigital HealthHealthtechSaaS

RaNA Therapeutics in

BiotechCambridge, US

Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)

BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)

Co-investorsAtlas Venture

ReCode Therapeuticsrecodetx.com in 𝕏

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Co-investorsAju IB Investment EcoR1 Capital Evolution VC Partners MPM BioImpact OrbiMed OUP (Osage University Partners)+6 more

Resilienceresilience.com 𝕏

Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.

Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US

William S. Marth(Chief Executive Officer)William S. Marth, RPh., MBA(President & CEO)

Board Robert Nelsen(Chairman, Resilience; Founder, ARCH)

Co-investors8VC ARCH Venture Partners Catalio Capital Management, LP Global Health Investment Corporation GV (Google Ventures)Koch Disruptive Technologies +14 more

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Jan 2017

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)in Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in

Board Edward T. Mathers(Director)in Jonathan Silverstein(Director)in Neil Exter(Director)in

Co-investorsForesite Capital HEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)Wellington Management OrbiMed Third Rock Ventures

Saamasaama.com in 𝕏

Saama provides AI-based data analytics solutions and services for the life sciences industry, with a focus on accelerating clinical trials.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechSaaSCampbell, US

Suresh Katta(Executive Officer, Director)in Simon Ho(Executive Officer)in

Board Marc McMorris(Director)inKen Coleman(Director)Dan Fishback(Director)William Binch(Director)

Co-investorsCarrick Capital Partners Intermountain Health McKesson Ventures Merck Global Health Innovation Fund MSD Global Health Innovation Fund

Simcha Therapeuticssimchatx.com in

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

Aaron Ring(Executive Officer, Director)in Beatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsConnecticut Innovations SR One Capital Management Axial VC Biotechnology Value Fund Rock Springs Capital Samsara BioCapital

Springworkstxspringworkstx.com in 𝕏

SpringWorks is a biotechnology company focused on developing innovative treatments for cancer patients.

BiotechDigital HealthHealthtechMedical DevicesAustin, US

Co-investorsFrazier Life Sciences

STAT Dxqiagen.com in 𝕏

Qiagen manufactures enzymes and molecular biology products, plus scientific research tools and software for studying biological targets and pathways.

BiotechData & InfrastructureDigital HealthHealthtechMedical Devices

Co-investorsHarmonic Growth Partners Ysios Capital

Storm Therapeuticsstormtherapeutics.com in 𝕏

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.

BiotechHealthtechMedical Devices

Co-investorsCambridge Innovation Capital Fast Track Initiative M Ventures Seroba Life Sciences Taiho Ventures, LLC UTokyo Innovation Platform Co. Ltd.+3 more

Strata Oncologystrataoncology.com in 𝕏

Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.

AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US

Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)

Board Christopher O'Donnell(Director)inDavid Rubin(Director)in James Pavlik(Director)in

Co-investorsArboretum Ventures Baird Capital Merck Global Health Innovation Fund MSD Global Health Innovation Fund Wellington Management Deerfield Management Company +1 more

TRexBiotrex.bio in

TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.

AI & Machine LearningBiotechDeep TechHealthtech

Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)

Co-investorsAvego BioScience Capital Delos Capital Dementia Discovery Fund SV Health Investors Agent Capital Polaris Partners

Triana Biotrianabio.com in 𝕏

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & Chief Executive Officer)in

Co-investorsAscenta Capital Atlas Venture Lightspeed Venture Partners RA Capital Bessemer Venture Partners Pfizer Ventures +3 more

TRIMTech Therapeuticstrimtechtherapeutics.com in

TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.

BiotechDeep TechLongevityMedical DevicesCambridge, GB

Damian Crowther, PhD FRCP(Co-founder, Head of Research)Dr. Leo James(Co-founder, Group Leader at MRC Laboratory of Molecular Biology)Dr. William McEwan(Co-founder, Group Leader at UK Dementia Research Institute, University of Cambridge)Nicki Thompson, PhD(CEO)Nicki Thompson(CEO)

Co-investorsCambridge Innovation Capital Pfizer Ventures SV Health Investors M Ventures Start Codon Diamond Edge Ventures

Vibrant Therapeuticsvibrantx.com

Vibrant Therapeutics develops multispecific antibody-based prodrugs with conditional activation and targeted delivery for patients with oncological, autoimmune, and neurological diseases.

AI & Machine LearningBiotechHealthtech

Co-investorsPfizer Ventures

visit www.epicsciences.comepicsciences.com

UWIN33 is an online casino and slot-game platform offering slots, live casino, sports betting, and arcade games in the Thai-language market.

ConsumerGaming

visit www.reflexionmedical.comreflexionmedical.com in 𝕏

RefleXion Medical develops autonomous radiotherapy technology that uses biological signals from cancer cells to detect and treat solid tumors in the lung or bone.

BiotechHealthtechMedical DevicesHayward, US

Akshay Nanduri(Founder)Samuel Mazin(Founder)

Co-investorsSofinnova Partners Venrock

visit www.vectivbio.comvectivbio.com in 𝕏

Ironwood Pharmaceuticals is a gastrointestinal healthcare company developing treatments for GI diseases.

BiotechHealthtech

VitaDAO Privatevitadao.com 𝕏

VitaDAO is a decentralized autonomous organization that funds and coordinates longevity and aging research using AI agents, decentralized governance, and on-chain funding mechanisms such as IP-NFTs.

BiotechCrypto & Web3Longevity

Co-investorsCollab+Currency Sora Ventures Tioga Capital Partners

Vivet Therapeuticsvivet-therapeutics.com in 𝕏

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHealthCap Kurma Partners Novartis Venture Fund Roche Venture Fund Ysios Capital Columbus Venture Partners +1 more

WEX Healthwexhealthinc.com in 𝕏

WEX Health provides benefits administration technology and services, including enrollment, ACA and COBRA compliance, and reimbursement and savings accounts such as HSAs, FSAs, and HRAs.

FintechHR TechSaaS

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Accelerator CorporationAMRAAnjarium BiosciencesAquinox PharmaceuticalsAureon LaboratoriesAvid RadiopharmaceuticalsAviirBioGraph 55Blade Therapeutics Celladon ComplexaCydanCydan IIDIR TechnologiesDVS SciencesEpic SciencesEvolution BenefitsFlexion TherapeuticsFluidigmHandyLabHD BiosciencesIncendia TherapeuticsIxchelsis LimitedLodo TherapeuticsM2SMagnolia NeurosciencesMetabomedMorphic TherapeuticNational ResilienceNeuroneticsNodalityOTR TherapeuticsPalleon PharmaPetra PharmaQuartet MedicineSecond GenomeSpringWorks TherapeuticssuperDimensionSupplyScapeSystem1 BiosciencesTetraLogic PharmaceuticalsTherachonTriplet TherapeuticsVectivBiovisit https://www.otr-tx.comvisit www.anjarium.comvisit www.aqxpharma.comvisit www.avidrp.comvisit www.blademed.comvisit www.morphictx.comVitaDAOVtesseYumanity TherapeuticsZiarco Pharma

Exits · 18

12 IPOs · 6 acquisitions · showing 16

4D Molecular TherapeuticsNASDAQ: FDMTBolt BiotherapeuticsNASDAQ: BOLTCytomX TherapeuticsNASDAQ: CTMXEnliven TherapeuticsNASDAQ: ELVNGinkgo BioworksNYSE: DNAImaraNASDAQ: ELVNKymera TherapeuticsNASDAQ: KYMRMirna TherapeuticsOTC: SYBXNextCureNASDAQ: NXTCNovoCureNASDAQ: NVCRPyxis OncologyNASDAQ: PYXSSynlogicOTC: SYBXDVS Sciencesacq. by Fluidigm Corp.Epix Therapeuticsacq. by MedtronicImcheckacq. by ClementiaJnana Therapeuticsacq. by Otsuka

Portfolio news

latest coverage across their companies

Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer

Flare Therapeutics · globenewswire.com · Jun 30, 2026

Arrakis Therapeutics Announces CEO Transition with Mark DeLong Appointed as New CEO - BioSpace

Arrakis Therapeutics · biospace.com · Jun 25, 2026

Vibrant Therapeutics - BIO International Convention 2026

Vibrant Therapeutics · convention.bio.org · Jun 23, 2026

Enara Bio raises $53M Series B — Biotech funding UK 2026 | Scaling Europe

Enara Bio · scalingeurope.co.uk · Jun 2, 2026

Cartography Biosciences Receives Investment From Samsung Ventures

Cartography Biosciences · finsmes.com · May 7, 2026

Pipeline - FoRx Therapeutics

FoRx Therapeutics · forxtherapeutics.com · Feb 16, 2026

Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform - Enodia Therapeutics

Enodia Therapeutics · enodiatx.com · Jan 8, 2026

Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio

Mediar Therapeutics · prnewswire.com · Jan 7, 2026

Frequently asked questions

How many investments has Pfizer Venture Investments made?: Pfizer Venture Investments has 148 tracked investments, 18 of which have exited.
What stage does Pfizer Venture Investments invest at?: Pfizer Venture Investments invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Pfizer Venture Investments's typical check size?: Pfizer Venture Investments typically writes checks of $5M – $20M.
What sectors does Pfizer Venture Investments focus on?: Pfizer Venture Investments focuses on AI & Machine Learning, Biotech, Healthtech, Medical Devices.
Does Pfizer Venture Investments lead rounds?: Yes, Pfizer Venture Investments leads investment rounds.
Who does Pfizer Venture Investments co-invest with?: Pfizer Venture Investments most often shares deals with New Enterprise Associates (NEA), RA Capital, OUP (Osage University Partners), among 198 tracked co-investors.

Co-investors · 31

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 13

Enliven Therapeutics Imara Mirna Therapeutics Synlogic Clovis Oncology Complexa Cydan II Mersana Therapeutics NexImmune Resilience Rhythm PharmaceuticalsTherachonVtesse

$200K – $40M

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 12

Bolt Biotherapeutics Enliven Therapeutics ImaraPyxis OncologyArtios Pharma Capstan Therapeutics Enara Bio Interius BioTherapeutics Jnana Therapeutics Merus Triana BioNimbus Therapeutics

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 10

CytomX Therapeutics Enliven Therapeutics Imara Mirna Therapeutics NextCure Synlogic Enlaza Therapeutics ReCode Therapeutics Rhythm Pharmaceuticals SpringWorks Therapeutics

$1M – $75M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 8

Artios Pharma Mediar Therapeutics Mission Therapeutics Mozart Therapeutics ReflexionmedicalCortexymeVectivBiovisit www.reflexionmedical.com

$540K – $27M

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 7

Kymera Therapeutics Synlogic Arkuda Therapeutics RaNA Therapeutics Triana BioNimbus TherapeuticsTriplet Therapeutics

$500K – $1M

Samsara BioCapital

Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.

Both backed · 7

Bolt Biotherapeutics Autobahn Therapeutics, Inc.Enara Bio Enlaza Therapeutics Normunity Simcha Therapeutics SpringWorks Therapeutics

SR One Capital Management

SR One Capital Management is a life sciences venture capital firm that takes a 'back-and-build' approach, providing entrepreneurs with human, intellectual, and financial resources. It emerged from the legacy SR One team formerly part of GSK.

Both backed · 6

Mission Therapeutics Palleon Pharmaceuticals Simcha TherapeuticsMorphic TherapeuticNimbus TherapeuticsSecond Genome

Third Rock Ventures

Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.

Both backed · 5

CytomX Therapeutics Flare Therapeutics Rhythm Pharmaceuticals Triana BioAblexis

$100K – $5M

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, primarily in biotechnology and biopharmaceuticals, at various stages of development across North America and Europe.

Both backed · 5

Anaveon Artios Pharma FoRx Therapeutics Mediar Therapeutics Vivet Therapeutics

$5M – $25M

Avoro Capital Advisors

Avoro Capital Advisors is an investment firm focused on healthcare and life sciences, pursuing scientific breakthroughs that address unmet medical needs.

Both backed · 5

Kymera Therapeutics Mersana Therapeutics Merus NormunityTherachon

Polaris Partners

Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.

Both backed · 4

Crossbow Therapeutics Jnana Therapeutics Montis BiosciencesTRexBio

$500K – $5M

Andera Partners

Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.

Both backed · 4

Artios Pharma Complexa Grey Wolf Therapeutics Imcheck

▶19 more co-investors

MPM BioImpact Bessemer Venture Partners EQT Life Sciences Forbion Kurma Partners Pureos Bioventures AME Cloud Ventures Earlybird Venture Capital Omega Funds Redpoint Ventures HCVC Bling Capital Webb Investment Network Xtripe Angels M12 (Microsoft's Venture Fund)The Column Group Zintinus Innovation Works Riverfront Ventures, LLC

Firms observed investing alongside Pfizer Venture Investments, from public investor directories. Shared companies are the overlap with Pfizer Venture Investments's recorded portfolio.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Menlo Ventures

Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.

$1M – $20M

Norwest Venture Partners

Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.

$10M – $30M

Ambix Venture Management, Llc

Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.

Featured in lists

Seed Investors & VC Firms Series A Investors & VC Firms AI & Machine Learning Investors & VC Firms Growth Investors & VC Firms Healthtech Investors & VC Firms AI & Machine Learning Seed Investors & VC Firms Healthtech Seed Investors & VC Firms Series B Investors & VC Firms AI & Machine Learning Series A Investors & VC Firms Biotech Investors & VC Firms Healthtech Series A Investors & VC Firms Biotech Seed Investors & VC Firms